Voyager Therapeutics Announces First Quarter 2024 Conference Call and Webcast
06 Mayo 2024 - 6:00AM
Voyager Therapeutics, Inc. (Nasdaq: VYGR), a biotechnology company
dedicated to advancing neurogenetic medicines, today announced it
will report first quarter 2024 financial and operating results
after market close on Monday, May 13, 2024. Subsequently, the
Company will host a conference call and webcast at 4:30 p.m. ET to
review its financial and operating results.
To participate via telephone and join the call live, please
register in advance here:
https://register.vevent.com/register/BI1f6af80e7a614ca7925cbad2f35a55c6.
Upon registration, telephone participants will receive a
confirmation email detailing how to join the conference call,
including the dial-in number and a unique passcode. A live webcast
of the call will also be available on the Investors section of the
Voyager website at ir.voyagertherapeutics.com, and a replay of the
call will be available at the same link approximately two hours
after its completion. The replay will be available for at least 30
days following the conclusion of the call.
About Voyager Therapeutics
Voyager Therapeutics, Inc. (Nasdaq: VYGR) is a biotechnology
company dedicated to leveraging the power of human genetics to
modify the course of – and ultimately cure – neurological diseases.
Our pipeline includes programs for Alzheimer’s disease, amyotrophic
lateral sclerosis (ALS), Parkinson’s disease, and multiple other
diseases of the central nervous system. Many of our programs are
derived from our TRACER™ AAV capsid discovery platform, which we
have used to generate novel capsids and identify associated
receptors to potentially enable high brain penetration with genetic
medicines following intravenous dosing. Some of our programs are
wholly owned, and some are advancing with partners including
Alexion, AstraZeneca Rare Disease; Novartis Pharma AG; Neurocrine
Biosciences, Inc.; and Sangamo Therapeutics, Inc. For more
information, visit www.voyagertherapeutics.com.
Voyager Therapeutics® is a registered trademark, and TRACER™ is
a trademark, of Voyager Therapeutics, Inc.
Contacts
Trista Morrison, NACD.DC, tmorrison@vygr.com Investors: Adam
Bero, Ph.D., abero@kendallir.com Media: Brooke Shenkin,
brooke@scientpr.com
Voyager Therapeutics (NASDAQ:VYGR)
Gráfica de Acción Histórica
De May 2024 a Jun 2024
Voyager Therapeutics (NASDAQ:VYGR)
Gráfica de Acción Histórica
De Jun 2023 a Jun 2024